The Medical Letter on Drugs and Therapeutics
Silodosin (Rapaflo) for Benign Prostatic Hyperplasia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Silodosin (Rapaflo – Watson Pharmaceuticals), an alpha1a-adrenoreceptor selective antagonist, has been approved by the FDA for treatment of benign prostatic hyperplasia (BPH). Some medications for BPH are listed in the table on page 4. Alpha1 blockers are commonly used with 5α-reductase inhibitors such as finasteride, which can shrink the size of the prostate, but may take months to do so.1

MECHANISM OF ACTION — Non-selective alpha1 blockers antagonize alpha1a adrenoreceptors in the bladder neck and prostate, helping relax smooth muscle tone and relieving obstructive urinary symptoms, and also inhibit alpha1b adrenoreceptors in vascular smooth muscle, causing relaxation of vascular tone, postural hypotension and syncope. The selective alpha1a antagonism of silodosin is claimed to reduce bladder tone with less risk ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Silodosin (Rapaflo) for Benign Prostatic Hyperplasia
Article code: 1303c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian